Clover Health Investments, Corp. (NASDAQ: CLOV) has announced the launch of Counterpart Assistant (CA), a new SaaS and tech-enabled services solution aimed at extending the benefits of data-driven technology and personalized care to a wider audience, including healthcare providers outside Clover Health's Medicare Advantage plan.
The new offering, which employs a hybrid SaaS and shared-savings model, with options for full capitation, is expected to broaden Clover's impact on patient care and operational efficiency, providing a new pathway to growth leveraging its existing technology assets.
Key highlights of the announcement include: Clinicians using Counterpart Assistant see over 1,000 basis point differential in medical cost ratios. Retrospective data analyses have revealed a significant association between CA use and early diagnosis of diabetes and chronic kidney disease, as well as improved medication adherence. * Counterpart Health, a subsidiary of Clover Health, will provide full implementation support, including training, integration assistance, and ongoing technical support, leveraging Clover’s extensive experience with its own MA plan.
Andrew Toy, CEO of Clover Health, expressed pride in CA's clinical improvements and the progress it brings to value-based care, noting that the mission and business progress are measured by the number of lives managed by primary care physicians using CA technology.
The press release indicates that Counterpart’s proprietary technology platform is now live with its first clinician users in external software-as-a-service (SaaS) and value-based arrangements, supporting clinicians in a range of practices, from large integrated health systems to small, ACO-affiliated community practices.
These new developments are part of Clover Health's commitment to bringing access to great healthcare to everyone on Medicare, with a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Clover's strategy is powered by its software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. Today the company's shares have moved -0.5% to a price of $1.0. If you want to know more, read the company's complete 8-K report here.
